Lambert-Eaton Myasthenic Syndrome.

Link to article at PubMed

Related Articles

Lambert-Eaton Myasthenic Syndrome.

Neurol Clin. 2018 May;36(2):379-394

Authors: Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ

Abstract
Lambert-Eaton myasthenic syndrome is a paraneoplastic or primary autoimmune neuromuscular junction disorder characterized by proximal weakness, autonomic dysfunction and ariflexia. The characteristic symptoms are thought to be caused by antibodies generated against the P/Q-type voltage-gated calcium channels present on presynaptic nerve terminals and by diminished release of acetylcholine. More than half of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung carcinoma. Diagnosis is confirmed by serologic testing and electrophysiologic studies. 3,4-diaminopyridine is effective symptomatic treatment of LEMS.

PMID: 29655456 [PubMed - in process]

Leave a Reply

Your email address will not be published.